<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Rejuvenate Bio — Prospect Detail</title>
  <link rel="stylesheet" href="styles.css">
</head>
<body>
<header class="site-header"><h1>Prospect Detail</h1></header>
<div class="container">
  <a href="index.html" class="back-link">&larr; Back to All Prospects</a>
  <div class="detail-header">
    <span class="badge health" style="font-size:.8rem;">Digital Health</span>
    <h1>55. Rejuvenate Bio</h1>
    <p class="meta">Anti-Aging Gene Therapy</p>
  </div>
  <div class="section"><h3>1. Startup Name</h3><p><strong>Rejuvenate Bio</strong></p></div>
  <div class="section"><h3>2. Founder Contact</h3><p><strong>Wyss Institute Team</strong></p><p>Wyss Institute for Biologically Inspired Engineering at Harvard</p><p>Co-founded with Dr. George Church, Harvard genetics pioneer</p></div>
  <div class="section"><h3>3. Product Overview</h3><p>Rejuvenate Bio develops gene therapy to treat age-related conditions, starting with companion animals like dogs. The company uses gene therapy to deliver combinations of longevity-associated genes, aiming to extend healthy lifespan and treat age-related diseases in pets before translating to humans.</p></div>
  <div class="section"><h3>4. Funding Stage</h3><p><strong>Series A</strong> — Raised $10M+ to advance veterinary gene therapy programs.</p></div>
  <div class="section"><h3>5. How I Found the Company</h3><p>Discovered through Wyss Institute spinout company portfolio and longevity research coverage.</p></div>
  <div class="strengths-weaknesses">
    <div class="section"><h3>Strengths</h3><ul><li><strong>Pet market entry:</strong> Veterinary pathway allows faster validation with lower regulatory burden.</li><li><strong>Star power:</strong> George Church association brings credibility and attention.</li></ul></div>
    <div class="section"><h3>Weaknesses</h3><ul><li><strong>Unproven science:</strong> Longevity gene therapy remains highly experimental.</li><li><strong>Ethical concerns:</strong> Human anti-aging interventions face significant public scrutiny.</li></ul></div>
  </div>
  <div class="section"><h3>7. Five Questions for the Team</h3><ol class="questions-list"><li>What results have you seen in canine trials?</li><li>Which specific age-related conditions are you targeting first?</li><li>What is your timeline for human applications?</li><li>How do you price gene therapy for pet owners?</li><li>What safety data do you have on multi-gene therapy approaches?</li></ol></div>
  <a href="index.html" class="back-link">&larr; Back to All Prospects</a>
</div>
</body>
</html>
